ZYME Stock Analysis: Buy, Sell, or Hold?

ZYME - Zymeworks Inc.

PHARMACEUTICAL PREPARATIONS
$24.35
0.24 (1.00%) ▲
5d: -1.77%
30d: -9.07%
90d: -3.49%
HOLD
MODERATE Confidence
Protect Your ZYME Gains
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Aug 06, 2026

Get Alerted When ZYME Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
📊 HOLD: ZYME shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$1.68
Based on -29.3% avg growth
INTRINSIC VALUE TODAY
$1.04
Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: ZYME is currently trading at $24.35, which is considered slightly low relative to its 30-day fair value range of $24.26 to $27.27. From a valuation perspective, the stock is trading at a discount (Forward PE: 47.2) compared to its historical average (63.3). Remarkably, the market is currently pricing in an annual earnings decline of 9.3% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, ZYME is in a uptrend. The price is currently testing key support at $23.93. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: ZYME has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $40.15 (+64.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position SLIGHTLY LOW
Historical Trading Range $24.26 - $27.27
Company Quality Score 55/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 57.1%

Protect Your Profits

Holding ZYME? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

  • BULLISH: Price oversold vs 30-day range
  • BEARISH: Weak technical setup (25/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 64.9% below Wall St target ($40.15)

Trading Range Analysis

30-Day Trading Range $24.26 - $27.27
Current vs Trading Range SLIGHTLY LOW

Support & Resistance Levels

Support Level $23.93
Resistance Level $26.19
Current Trend Uptrend
Technical data as of Jun 3, 2026

Fundamental Context

Forward P/E (Next Year Est.) 47.22
Wall Street Target $40.15 (+64.9%)
Revenue Growth (YoY) -91.1%
Profit Margin -126.3%
Valuation Discount vs History -9.3% cheaper
PE vs Historical 47.2 vs 63.3 CHEAP
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -9.3% (market-implied from PE analysis)
1-Year Target $22.09 (-9%)
2-Year Target $20.03 (-18%)
3-Year Target $18.17 (-25%)
3-Yr Target (if PE normalizes) (PE: 47→63) $24.36 (0%)
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 47.2, Growth: -62.5%) $17.75 (+-27%)
Base: (SPY PE: 21.9, Growth: -62.5%) $8.24 (-66%)
Bear: (PE: 18.6, Growth: -62.5%) $7.00 (-71%)
💡 Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 47.2 to 63.3
Stabilization Target: $32.64 (+34.1%)
PE Expansion Potential: +34.1%
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: June 03, 2026 5:57 PM ET
Data refreshes hourly during market hours. Next update: 6:57 PM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Jeffrey T L Smith SELL 9310 shares 2026-01-12
Kenneth Galbraith SELL 30424 shares 2026-01-12
Mark Hollywood SELL 6120 shares 2026-01-12

Unlock Insider Activity

See real-time buying/selling by company executives for ZYME.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
LEGN
Legend Biotech Corp
STRONG BUY
22 analysts
$55 66 BUY
REGN
Regeneron Pharmaceutical…
STRONG BUY
25 analysts
$833 58 HOLD
VRTX
Vertex Pharmaceuticals I…
BUY
34 analysts
$548 53 HOLD
XENE
Xenon Pharmaceuticals Inc
STRONG BUY
19 analysts
$79 55 HOLD
RARE
Ultragenyx
STRONG BUY
20 analysts
$52 53 HOLD

Advanced ZYME Option Strategies

Professional options setups generated by AI based on today's ZYME price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for ZYME

ZYME Technical Chart ZYME Price Prediction ZYME Earnings Date ZYME Investment Advisor ZYME Fair Price Analyzer ZYME Options Advisor ZYME Options Chain ZYME Options Analysis ZYME Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals